- Report
- April 2024
- 262 Pages
Global
From €7636EUR$7,950USD£6,574GBP
- Drug Pipelines
- April 2024
- 80 Pages
Global
From €1441EUR$1,500USD£1,240GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1441EUR$1,500USD£1,240GBP
- Report
- November 2023
- 30 Pages
Global
From €3122EUR$3,250USD£2,687GBP
- Report
- February 2023
- 188 Pages
Global
From €7203EUR$7,500USD£6,202GBP
- Report
- February 2023
- 94 Pages
Global
From €3794EUR$3,950USD£3,266GBP
- Report
- September 2022
- 30 Pages
Global
From €2641EUR$2,750USD£2,274GBP
- Report
- May 2024
- 187 Pages
From €4706EUR$4,900USD£4,052GBP
- Report
- June 2021
- 50 Pages
China
From €2497EUR$2,600USD£2,150GBP
- Drug Pipelines
- March 2023
- 150 Pages
Global
From €10560EUR$10,995USD£9,092GBP
- Report
- April 2022
- 85 Pages
Global
From €3500EUR$3,904USD£3,119GBP
- Report
- January 2021
- 140 Pages
China, Global
From €3000EUR$3,346USD£2,673GBP
- Report
- February 2024
- 180 Pages
Global
From €5282EUR$5,499USD£4,547GBP
Ruxolitinib is a type of hematological drug used to treat myelofibrosis, a type of bone marrow disorder. It works by blocking certain proteins that cause inflammation and scarring in the bone marrow. Ruxolitinib is also used to treat polycythemia vera, a rare blood disorder. It is taken orally and is available in both tablet and liquid form.
Ruxolitinib is a relatively new drug, having been approved by the US Food and Drug Administration in 2011. It is the first and only approved Janus kinase (JAK) inhibitor for the treatment of myelofibrosis. It has been shown to reduce symptoms of the disease, such as enlarged spleen, fatigue, and night sweats.
The ruxolitinib market is growing rapidly, with more and more patients being prescribed the drug. It is becoming increasingly popular due to its effectiveness and safety profile.
Some companies in the ruxolitinib market include Incyte Corporation, Novartis, and Pfizer. Show Less Read more
